- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
比美替尼(Binimetinib)的用药周期需根据疾病进展、耐受性及治疗效果动态调整，通常需持续用药直至疾病恶化或出现不可耐受毒性。以下从用药时长判断依据、中断标准及特殊情况下长期用药管理三方面具体说明。 1适应症 (1)黑色素瘤：与康奈非尼联用治疗BRAFV600E/K突变阳...
There are multiple restrictions on the use of Binimetinib, including contraindications for special populations, dosage adjustment requirements,...
Binimetinib is an oral MEK1/MEK2 kinase inhibitor that needs to be used in combination with Conafenib. It is mainly used to treat BRAFV600E/K m...
Binimetinib, as a MEK inhibitor, commonly has multiple systemic side effects that require different mitigation measures based on their severity...
Pacritinib is an oral kinase inhibitor primarily used to treat hematological malignancies such as myelofibrosis. This drug targets the JAK2/FLT...
Pacritinib has shown significant efficacy in the treatment of hematological malignancies such as myelofibrosis, especially in patients with t...
Canaglu hydrochloride is a urinary tract anti infective drug targeting the METAP2 target, mainly used to treat urinary tract infections caused ...
The conventional dose of Canaglu hydrochloride is 1-3 pills per day, and the specific dosage needs to be adjusted according to the indications....
Quizartinib is an FLT3 tyrosine kinase inhibitor mainly used to treat specific types of acute myeloid leukemia. Its standard dose needs to be a...
Quizartinib, as an FLT3 inhibitor, commonly has side effects including hematological toxicity, prolonged cardiac QT interval, and gastrointesti...
